Publications by authors named "C Paez"
Utilizing transiently transfected cell lines could significantly reduce manufacturing timelines for protein subunit vaccines. This trial compared safety and immunogenicity of human immunodeficiency virus (HIV) envelope CH505TF gp120 vaccines produced by upstream stable and transient transfection (each admixed with GLA-SE adjuvant, a TL4 agonist). Both vaccines were safe and well tolerated.
View Article and Find Full Text PDFBackground: Multiple broadly neutralising monoclonal antibodies (mAbs) are in development for HIV-1 prevention. The aim of this trial was to test the PGT121.414.
View Article and Find Full Text PDFArticle Synopsis
- To prevent HIV-1 transmission, high levels of broadly neutralizing antibodies are necessary at mucosal sites of exposure, particularly in the colorectal and genitourinary tracts.
- A study compared the biodistribution of two monoclonal antibodies, VRC01 and its longer-lasting variant VRC01LS, over 1-52 weeks post-infusion, finding VRC01LS levels significantly higher in various tissues at earlier and later time points.
- While both antibodies are mainly retained in rectal and cervical tissue, only a small percentage reaches seminal and rectal secretions; VRC01LS shows a longer elimination half-life, indicating its potential for sustained protection against HIV-1.
Background: Broadly neutralizing antibodies (bnAbs) are a promising approach for HIV-1 prevention. In the Antibody Mediated Prevention (AMP) trials, a CD4-binding site targeting bnAb, VRC01, administered intravenously (IV), demonstrated 75% prevention efficacy against highly neutralization-sensitive viruses but was ineffective against less sensitive viruses. VRC07-523LS is a next-generation bnAb targeting the CD4-binding site and was engineered for increased neutralization breadth and half-life.
View Article and Find Full Text PDFPurpose: Sexual distress impacts the quality of life (QoL) of breast cancer patients but is often overlooked in standard care pathways. This study evaluated the prevalence and factors of sexual distress among Dutch breast cancer patients, compared them to the general population, and explored how sexual distress is discussed in clinical settings from the perspectives of patients and healthcare professionals (HCPs).
Methods: Questionnaires containing the Female Sexual Distress Scale (FSDS) and demographic variables were distributed to women with breast cancer.